Trial
NCT05516498
Zibotentan and Dapagliflozin Combination, EvAluated in Liver Cirrhosis (ZEAL Study)
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
AstraZeneca
Collaborators
—
Condition
Liver Cirrhosis
Intervention
Part A: Placebo (matching zibotentan capsule & matching dapagliflozin tablet)
Why stopped
The study was ended earlier than planned due to a sponsor decision.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-08-15